Patent · US Active

Replication-enhanced oncolytic adenoviruses

US11951141B2 · kind B2 · utility

0Cited by

0References

7Claims

0Family size

Assignees

MEMGEN, INC. · US
H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE INC. · US

Inventors

Mark J. Cantwell · San Diego, US
Amer A. Beg · Tampa, US

Key dates

Filing date	Nov 6, 2020
Grant date	Apr 9, 2024
Priority date	—
Expiry date	Sep 26, 2042

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2830/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Disclosed are replication-enhanced oncolytic adenoviruses. These oncolytic adenoviruses have tumor-specific replication capable of enhanced tumor oncolysis and enhanced therapeutic transgene expression. Also disclosed are methods comprising administering a replication-enhanced oncolytic adenovirus for patients suffering from a cancer.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.